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Abstract 
We present in vitro and in vivo studies of yttrium-90 (90Y)-labelled human serum albumin 
magnetic microspheres (HSAMMS) as multifunctional agent for bimodal radionuclide-
hyperthermia cancer therapy. The HSAMMS were produced using a modified emulsification-
heat stabilization technique and contained 10-nm magnetite nanoparticles coated with citric acid, 
distributed as inhomogeneous clusters within the albumin microspheres. The average particle 
size of the complete HSAMMS was 20 µm, and they exhibited superparamagnetic behavior at 
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room temperature. The stability of the 90Y-labelled HSAMMS was investigated in vitro (in saline 
and human serum) and in vivo by analyzing their biodistribution in normal Wistar rats. The in 
vitro experiments revealed the high stability of the labelled HSAMMS in saline and human 
serum after 72 h. Following the intravenous administration of the 90Y-HSAMMS in rats, 88.81% 
of the activity localizes in the lungs after 1 h, with 82.67% remaining after 72 h. These data on 
90Y-HSAMMS provide good evidence for their potential use in bimodal radionuclide-
hyperthermia cancer therapy.  
 
1. Introduction 
Huge progress in nanoscience and nanotechnology has led to the development of new, 
nanostructured materials with properties that promise breakthroughs in a vast number of 
potential applications. Furthermore, it has fostered the emergence of a new field, i.e., 
nanomedicine, with the potential for providing revolutionary approaches to the diagnosis and 
treatment of some fatal diseases. In particular, magnetic nanoparticles (MNPs) are finding 
increasing interest in a broad range of biomedical applications, including magnetic targeting, 
drug and gene delivery, magnetic separation, magnetic resonance imaging, and hyperthermia. 
MNPs have led to a novel therapy known as thermotherapy, recently approved for clinical use 
[1,2]. This new protocol uses magnetic nanoparticles for heating a body region through the 
application of alternating magnetic fields (AMF) and the energy absorption of single-domain 
MNPs as result of Arrhenius-Néel relaxation [3,4]. Furthermore, it has been reported that MNPs 
can be incorporated inside target cells to provoke a large decrease in cell viability, with no 
detectable increase of temperature in the cell medium [5,6,7]. A large fraction of work on 
hyperthermia therapy involves magnetite nanoparticles, because they are highly biocompatible, 
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cheap, and can be made in a variety of ways. However, their use in therapy is limited, mainly due 
to the nonspecific targeting. Also, due to their tendency to agglomerate or to be rapidly covered 
with plasma proteins in the blood, they are quickly cleared by macrophages before they can 
reach the target cells [8]. The specific targeting can be improved either by tuning the particle 
size, which determines the particles’ preference for a specific organ [8], or by using a large 
magnetic-field gradient that is capable of retaining the MNPs within the application volume 
around and inside the target location [6, 7].  
 Albumin microspheres have received a lot of attention in recent decades as efficient 
drug-delivery vehicles because they are easy to prepare in defined sizes and carry reactive groups 
(amino and carboxylic groups) on their surfaces that can be used for radionuclide, chelator, 
antibodies binding and/or other surface modifications. Loaded with a sufficient amount of 
magnetite nanoparticles these microspheres might be used in hyperthermia treatment at a 
localized disease site where they could be delivered, after intravenous injection, by either passive 
means (e.g., trapping by size) or active means (e.g., magnetic targeting). Since hyperthermia 
alone is ineffective in most cases of cancer it needs to be combined with other forms of cancer 
therapy, such as radiation therapy. Hyperthermia may make some cancer cells more sensitive to 
radiation or harm other cancer cells that radiation cannot damage. When hyperthermia and 
radiation therapy are combined, they are often given within an hour of each other [ 9].  
Albumin microspheres currently have many clinical applications as carriers of diagnostic 
and therapeutic radionuclides. Labelled with 99mTc they are routinely used for lung-perfusion 
scintigraphy [10], while by labelling with 188Re they could be applied in internal radiation 
therapy [11, 12, 13, 14]. Furthermore, albumin microspheres have been used as carriers of 67Ga 
[15], 68Ga [16], 177Lu, 86Y and 90Y [17]. In these cases, chelators were attached onto the surface 
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of the spheres and the particles were labelled by subsequent complexation of the radionuclides. 
In this work yttrium-90 (90Y) was selected for the labelling of HSAMMS as a clinically 
acceptable, long-range, β-emitting radionuclide with optimal nuclear-physical characteristics for 
use in radionuclide therapy. Yttrium-90 is a pure, high energy β-emitter (Emaxβ of 2.27 MeV) 
with a half-life of 64.1 h [18] and it can produce biological damage over a distance that is 
determined by the range of the radionuclide emission (mean/maximum penetration depth is 
3.6/11 mm in the soft tissue) [19]. There are currently two commercially available 90Y-
microsphere products – glass microspheres [20] and resin microspheres [21] – that are clinically 
useful for the selective internal radiation treatment (SIRT) of primary and metastatic liver cancer 
[22]. Besides being used in radionuclide therapy, radionuclides provide opportunities for the 
investigation of the physicochemical properties and biodistribution patterns of newly developed 
nano- and micro-particles [23].  
This study reports on the synthesis of human serum albumin microspheres with 
encapsulated citric acid-coated magnetite nanoparticles and their effective labelling with 90Y for 
possible use in bimodal radionuclide and hyperthermia cancer therapy. We discuss the results 
from the structural and magnetic characterization as well as their efficiency as heating agents 
through specific power-absorption measurements. Finally, the results from a series of in vitro 
stability studies in saline and human serum as well as in vivo biodistribution studies of 90Y-
HSAMMS in Wistar rats are presented. 
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2. Experimental details 
2.1. Chemicals 
In the experiment we used the following: ferric chloride anhydrous (FeCl3 >99%, Fluka), 
ferrous chloride tetrahydrate (FeCl2 x 4H2O >99%, Sigma-Aldrich), ammonium hydroxide (25 
wt%, Zorka, Serbia), citric acid (Zorka, Serbia), cottonseed oil (Beohemik, Serbia), and diethyl 
ether anhydrous (Baker, Holland). Purified deionized water was prepared by the Milli-Q system 
(Millipore Co., Billerica, MA, USA). The human serum and human serum albumin were 
obtained from the National Blood Transfusion Institute (Belgrade, Serbia). The 90YCl3 was 
purchased from Polatom, Poland, in a no-carrier-added form (29.64 GBq cm-3 in 0.05 M HCl).  
 
2.2. Synthesis of magnetite and citric acid-coated magnetite nanoparticles  
Citric acid-coated magnetite nanoparticles were prepared using a two-step approach 
(post-synthesis coating) [24-26] and a co-precipitation method initially developed by Massarat 
[27]. Aqueous solutions (20 ml each) of 0.1 M FeCl2·4H2O and 0.2 M FeCl3 were mixed 
together, followed by the drop-wise addition of NH4OH (25% w/w) up to pH 10 under vigorous 
stirring and heating at 80 °C for 30 min. The resulting magnetite (Fe3O4) precipitate, retrieved by 
magnetic decantation, was washed several times with deionized water until neutral pH. After the 
magnetite synthesis, the coating reaction was carried out by the addition of 1 ml of a 1M citric 
acid solution. The temperature was raised to 90 °C and under continuous stirring for 90 minutes 
a stable suspension of citric acid-coated magnetite particles, i.e., ferrofluid, was obtained.  
 
 
 
6 
 
2.3. Preparation of HSAMMS 
 HSAMMS were prepared using an emulsification technique, described previously [28] 
with slight modifications, and stabilized by heat denaturation. Cottonseed oil was used as the oil 
phase and a mixture of HSA (1ml 20% HSA) and the previously prepared ferrofluid (0.5 ml, 88 
mg) as the water phase. The HSA-ferrofluid mixture was added slowly (during 10 min) dropwise 
with a syringe using a 21-gauge needle into the cottonseed oil at room temperature and 
vigorously stirred for 30 min. Afterwards the temperature was increased to 100 °C and the 
mixture was stirred for another 30 min. This resulted in the rapid evaporation of the existing 
water and the albumin’s irreversible denaturation, causing the formation of solid microspheres. 
The HSAMMS were filtered on Whatman No.5 filter paper, washed several times with ether to 
remove any adherent oil and vacuum dried in a desiccator overnight. The final HSAMMS were 
stored at 4 °C until use. The uniformity of the size of the microspheres was checked with light 
microscopy.  
 
2.4. Experimental methods for characterization of the samples  
   An integrated study of the structure of the microspheres was made by combining 
complementary techniques, such as XRD, FESEM, SEM/FIB dual beam and HRTEM. FTIR 
spectroscopic analyses were carried out at room temperature using a Nicolet 380 
spectrophotometer in the spectral range 4000–400 cm−1, with a resolution of 4 cm−1. X-ray 
powder diffraction (XRPD) data were collected on a Philips PW1710 diffractometer. The data 
were collected in the angular range 10-70 º (2θ) with a step size of 0.06º and a counting time of 
50 s per step. The thermogravimetric (TGA) analyses were performed simultaneously (30-
1000 °C range) on a SDT Q600 TGA/DSC instrument (TA Instruments). The heating rates were 
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20 °C min–1 and the sample mass was less than 10 mg. The furnace atmosphere consisted of air 
at a flow rate of 100 cm3 min–1. 
Field-emission scanning electron microscopy (FESEM) was used in order to determine 
the morphology, size and size distribution of the HSAMMS. A Jeol JSM-7600F with a Schottky-
type emitter was used at an accelerating voltage of 1.5 kV. The internal structure of the 
HSAMMS particles was analyzed using a SEM/FIB dual-beam device (NovaTM 200 NanoLab, 
FEI Company). The two beams were configured to allow the SEM to provide high-resolution 
imaging of the surface of a cross-section cut into the sample with the FIB. 
High-resolution transmission electron microscopy (TEM) measurements were carried out 
using a Jeol JEM 2100 HR electron microscope operating at 200 kV. The samples were prepared 
by ultra-sonification in ethanol and deposited on a conventional carbon-covered copper HRTEM 
grid. After drying, the samples were examined by HRTEM.  
 Hysteresis loops were measured at 300 K in the zero-field-cooled (ZFC) regime using 
the Quantum Design SQUID-based magnetometer MPMS XL-5. 
 The microspheres were submitted to alternating magnetic fields (AMF) using a home-
made applicator, consisting of a resonant LC tank working at close to the resonant frequency. 
The specific power absorption (SPA) of the samples (f = 355 kHz, H = 47 kA/m) was measured 
inside a thermally insulated Dewar. Temperature data were taken using a fiber-optic temperature 
probe immune to the RF environment. Before each experiment, the temperature evolution was 
measured for 5-10 min, with the RF source turned off, in order to establish a T-baseline.  
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2.5. Labelling of HSAMMS with yttrium-90 
For the radiolabelling of HSAMMS, to a suspension of 10 mg of HSAMMS in 1 ml at pH 
4.2, 5 μl of 90YCl3 solution containing approximately 370 MBq was added. The suspension was 
shaken and heated at 80 °C for 30 min. Labelled HSAMMS were then recovered by magnetic 
decantation and washed once with water to eliminate the unbound 90Y3+. The final 90Y- 
HSAMMS were re-suspended in 2ml of 0.9 % NaCl solution (saline) and used in the subsequent 
studies.  
The labelling yield was determined as the ratio of the measured HSAMMS-associated 
activity obtained after magnetic separation and the known activity used for the labelling. The 
radiolabelled particles were magnetically precipitated, but because of the risk of withdrawing 
labelled HSAMMS, the supernatant was not removed completely, so the activity was measured 
separately in a 0.1 ml aliquot of the supernatant and the remaining sample (radiolabelled 
HSAMMS and 1.9 ml supernatant). The acquired radioactivity was calculated as follows: the 
activity of the remainder – the activity of the 0.1 ml supernatant x1.9. Another method used for 
the determination of the unbound 90Y3+ present in the supernatant was instant thin-layer 
chromatography (ITLC) on silica-gel-impregnated glass-fiber sheets (SG) in normal saline, since 
it is a well-accepted and uncomplicated process to examine the radiopharmaceutical quality in 
nuclear medicine. In this condition, soluble free 90Y3+ moved to the solvent front (Rf =0.9-1.0), 
while the 90Y- HSAMMS remained at the origin (Rf =0.0-0.1). 
Since yttrium-90 is a pure β-emitter it can only be detected by “bremsstrahlung” [29, 30] 
measured in a cross-calibrated well counter Capintec CRC-15 beta counting calibrator (Ramsey, 
NJ USA) and well-type NaI(Tl) gamma counter (Wallac Compu Gamma Counter LKB, 
9 
 
Finland). The results are reported as the mean of at least three measurements ± standard 
deviation.  
 
2.6. In vitro stability of 90Y-labelled HSAMMS 
In vitro stability studies were performed by incubating 2 mg of 90Y-HSAMMS in 2 ml of 
either saline or human serum at 37 °C. At various times after the preparation the radiolabelled 
particles were magnetically precipitated and the activity was measured separately in a 0.1 ml 
aliquot of the supernatant and the remaining sample (radiolabelled HSAMMS and 1.9 ml 
supernatant). The HSAMMS bound radioactivity was calculated as follows: the activity of the 
remainder – the activity of the 0.1 ml supernatant x 1.9. The results of the HSAMMS-associated 
radioactivity were compared with a radiochromatography analysis performed on SG strips 
(ITLC-SG) with saline as the mobile phase at different times after the preparation for up to 94 h.  
 
2.7. Biodistribution and in vivo stability of 90Y-labelled HSAMMS  
  The entire animal study conformed to ethical guidelines and complied with the 
European Council Directive (86/609/EEC) and the rules for animal care proposed by the Serbian 
Laboratory Animal Science Association (SLASA). The animals were kept in a well-ventilated, 
temperature-controlled (22±1 °C) animal room for a few days prior to the experimental period 
and provided with food and water. Fifteen healthy Wistar rats (100±10 g body weight, 4 weeks 
of age, Institute of Biology, Vinča Institute of Nuclear Sciences) were intravenously injected 
with 0.1 ml of the microsphere suspension containing 0.1 mg of 90Y-HSAMMS (approx. 2.5 
MBq) through the tail vein. Five rats for each time point (1, 24, 72 h after injection) were 
sacrificed by cervical dislocation. The following organs were dissected out: muscle (hind leg), 
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bone (the complete left femur), heart, lungs, liver, kidneys, spleen, stomach (emptied) and 
intestine (emptied) and a blood sample (1ml). Selected organs and tissues were disintegrated and 
solubilized in a final volume of 10 ml to reach an identical geometry and similar probe density 
for bremsstrahlung measurements of the 90Y radioactivity. The uptake into the organs was 
expressed as a percentage of the injected total radioactivity (%ID/organ) and per ml of blood, 
except for the radioactivity in the muscle, which was estimated by assuming a muscle weight of 
40% of the total body weight. The amount of injected activity was calculated from the activity of 
the injection syringes before and after the injection because a significant quantity of the labelled 
microspheres stay attached to the plastics of the syringe. The results are reported as mean values 
± standard deviation.  
 
3. Results and discussion 
3.1. Magnetite and ferrofluid preparation  
In the absence of any surface coating, magnetic nanoparticles have hydrophobic surfaces 
with a large surface-area to volume ratio. Due to the hydrophobic interactions between the 
particles, they agglomerate and form large clusters with very strong magnetic dipole-dipole 
attractions among them [31]. In order to obtain a stable colloidal dispersion with the desired 
magnetic characteristics, different coating materials such as starch [32], polyethylene 
glycol/polyacril acid (PEG/PAA) [33], polylactic acid (PLA) [34], citric acid [35], oleic acid 
[36], decanoic acid and nonionic acid [37] have been applied. In the present study a citric acid 
coating was used to prevent the magnetite aggregation and to achieve good colloidal stability. 
The obtained citric acid-coated magnetite nanoparticles kept their colloidal characteristics for up 
to 3 months, with a very low level of sedimentation. It was assumed that citric acid can be 
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adsorbed onto the surface of the magnetite nanoparticles by coordinating ≡Fe-OH sites via one or 
two of the carboxylate functionalities, depending on the steric necessity and the curvature of the 
surface. The carboxylic acid group on the citric acid exposed to the solvent stabilized the fluids 
based on the electrostatic repulsion between the particles [38, 39, 40]. At a higher citric acid 
concentration a tighter packed surface structure can be supposed, e.g., instead of two, only one 
carboxylate group of citric acid will be bound to the ≡Fe-OH sites, forming the surface of 
magnetite particles [41]. Therefore, the presence of available carboxylic groups provides a route 
to an extended bond formation with albumin. Also, individual and separated magnetic 
nanoparticles allowed better encapsulation in the HSA microspheres than the aggregates. 
The representative FTIR measurements for citric-acid-coated magnetite nanoparticles and 
pure citric acid are shown in Fig. 1. The citric acid coating of the magnetite was confirmed by 
the presence of the peaks at 1560 and 1400 cm-1. The 1695 cm-1 peak, assignable to the C=O 
vibration (asymmetric stretching) from the COOH group in neat citric acid, after  the binding of 
the citric acid to the magnetite surface, was shifted to a lower wave number. The neighbor band 
at 1400 cm-1 was assigned to the symmetric stretching of C=O. The low-intensity peak at 540 
cm-1 can be associated with the stretching and torsion vibration modes of the magnetite. The 
large and intense band at approximately 3200 cm-1 could be assigned to the structural OH groups 
as well as to the traces of molecular water and citric acid.  
 
3.2. Preparation of the HSAMMS 
The microspheres and particles designed for use as radionuclide carriers in radionuclide 
therapy must comply with the high standards relating to biocompatibility and biodegradability. 
From the production side, they must be easy to radiolabel and provide a high radiochemical 
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stability of the labelled products against leaching of the radionuclide in vivo [42]. The high 
density of the 90Y-labelled glass microspheres used in the conventional therapy gave rise to 
problems during injection and, due to the non-biodegradability of the particles, they usually 
cause anatomical distress [43]. Resin microspheres are biocompatible but not biodegradable and 
suffer from a low specific activity, which requires the administration of large amounts of 
particles causing different adverse side-effects, like post-embolization syndrome [44]. To 
overcome these problems we synthesized biodegradable magnetic microspheres made from 
human serum albumin. Since the chemically cross-linked albumin microspheres showed non-
uniform sizes and aggregates and due to the fact that heat-stabilized HSAMMS were found to be 
more stable [45], in our preparation we used the thermal denaturation method. Higher 
temperatures and longer heating times generally produce harder, less porous and more slowly 
degradable spheres [46]. Patil also reported that the stabilization of albumin microspheres 
(without loaded magnetite) at low temperatures (100–105 °C) resulted in a less smooth spherical 
geometry and some irregularity in the shape than when stabilizing at a higher temperature (170–
175 °C) [46]. The reason for the smooth and compact surface of the albumin microspheres 
without magnetite is attributed to the preparation procedure in which the inner albumin phase of 
the water-in-oil emulsion was immediately solidified at high temperature with constant stirring. 
To investigate the effect of different temperatures on the geometry of the microspheres, the 
preparation of the HSAMMS was carried out at 100 °C and at higher temperatures (up to 170 
°C). All the HSAMMS batches gave the same rough surface morphology. Increasing the 
temperature to 170 °C does not affect the surface morphology and a smooth surface was not 
formed, probably due to the presence of magnetite.  
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We found that several factors determined the final magnetite loading of the microspheres, 
such as the magnetite-to-albumin ratio, the stirring rate of the emulsion and the average size of 
the MS. For the synthesis of the HSAMMS we used the highest possible ratio of ferrofluid to 
albumin (obtained in our experiments) in order to have a better magnetic response. Besides the 
amount of magnetite material, its location and long retention inside the albumin microspheres are 
important factors when considering the characteristics of any magnetic microspheres. Even 
microspheres with adsorbed magnetic particles will respond to an external magnetic field, but 
they would not be considered as a stable as the adsorbed magnetic particles may detach from the 
surface after their introduction to a physiological medium.  
 
3.3. Structure and thermal analysis of citric acid-coated magnetite and HSAMMS 
The crystal structure of the pure Fe3O4 as well as Fe3O4 in both citric acid-coated magnetite 
and HSAMMS was checked using the X-ray diffraction technique (XRD). Fig. 2 shows the XRD 
pattern of the HSAMMS. All the reflections of the crystalline Fe3O4 phase are indexed in the 
spinel space group Fd 3 m. No contamination by another phase was observed. The broad 
background is characteristic of amorphous HSA. The mean crystallite diameter of 11 nm was 
estimated for the Fe3O4 using Scherer’s equation and the peak half-height width of the (311) 
reflections. The same values were obtained for pure Fe3O4 and Fe3O4 in the citric acid-coated 
magnetite. 
Fig. 3 shows the TGA curves of the citric acid-coated magnetite and the HSAMMS (the 
corresponding derivatives are not shown). The thermogravimetric data showed that in the case of 
the coated NPs an initial weight loss of 6.1% (up to 127 °C) is due to the evaporation of 
physically adsorbed water. In the next step, up to 159 °C, the weight loss is 1.3%. The main step 
14 
 
along the decomposition process was observed in the interval 159–341 °C, with a weight loss of 
42%. No further weight loss was observed above 341 °C, with a mass residue of 49%. The 
product of the thermal degradation was some iron-oxide phase and some carbon-based residuals.  
The thermogravimetric curve of the HSAMMS showed that the thermal degradation 
occurs in three steps. A first step, related to dehydration, was observed up to 130 ºC, with a loss 
of weight of 9.8%. For the second (200–383 °C) and third (up to 580 °C) steps the observed 
weight loss was 33 and 51%, respectively. The final mass residue was 6% of the initial material, 
suggesting that the products of the thermal degradation were mainly Fe3O4 and residual carbon-
related compounds.  
 
3.4. FESEM, SEM/FIB and HRTEM analysis of magnetite, citric acid-coated magnetite 
and HSAMMS   
The morphology and internal composition of the HSAMMS were assessed by FESEM 
and dual-beam SEM/FIB microscopy. As can be seen from the secondary-electron images shown 
in Figures 4a and 4b the HSAMMS particles are spherically shaped with sizes spanning from 10 
to 70 µm. The surface of the microspheres is rough and, according to an energy-dispersive X-ray 
analysis (EDX), no detectable amounts of Fe-containing material can be found on their surface. 
The internal 3D distribution of the nanoparticles was analyzed by cross-sectioning a single 
microsphere using FIB, and further reconstruction of the slices into a 3D perspective (Figure 4 c, 
d). We found a cluster distribution of high-contrast areas corresponding to the magnetic 
nanoparticles inside the microsphere, as confirmed by an EDX analysis of these spots (see Fig. 
5).  
15 
 
Close to circumference some of the smaller spheres were electron transparent to the 
electron beam. Fig. 6 shows bright-field TEM images of the magnetite nanoparticles embedded 
in the organic matrix. It is mainly spherical particles that are seen, with a small amount of 
embedded aggregates. The magnetic nanoparticles appeared to be uniform in size from TEM 
images, with an average size of about 8–10 nm.  
 
3.5. Hysteresis loops   
The hysteresis loops of the samples M(H), recorded at 300 K, are shown in Fig. 7. The 
absence of any magnetization saturation was observed in all the samples. The M(H) curves 
showed  coercivity (HC) and remanence (Mr) values close to zero, indicating that the particles are 
superparamagnetic for a time scale of the order of seconds. The saturation magnetization MS 
value was estimated by extrapolation of the M vs. 1/H curve when 1/H → 0. We found that the 
sample Fe3O4 has MS = 61.5 emu/g, while Fe3O4/CA and HSAMMS have MS = 25 emu/g and MS 
= 2 emu/g, respectively. The values for the two last samples are the result of the presence of the 
organics, citric acid (CA) and citric acid with human serum albumin, and the reducing effective 
mass of magnetite. The fact that the HSAMMS are magnetic ensures that the engendered 
material, as an effective radionuclides carrier, can be moved under a moderate magnetic field 
strength. 
 
3.6. Labelling of HSAMMS with yttrium-90 
 The radio-tracer technique, possessing high sensitivity, credibility and freedom from 
interference, is a relevant approach to study the biodistribution of novel particles [47]. 
Nevertheless, there are still some limitations to the methods that can be used for radiolabelling 
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[48]. Firstly, the binding of the radionuclide has to be irreversible in order to prevent their escape 
to other tissues or organs. This problem exists even in newly developed, DOTA (1,4,7,10-
tetraazacyclododecane-N, N’,N’’,N’’’-tetraacetic acid) derived HSA microspheres, since the 
radiation induces the cleavage of the thiourea linker of the 90Y-DOTA-HSAMMS and makes it 
unsuitable for therapeutic applications [16]. Secondly, due to the necessarily short half-life time 
of 90Y, the manufacturing process is time limited and too complex because of the risk of 
contamination. The labelling of the HSAMMS was achieved by adding a YCl3 solution to a 
slightly acidic microsphere water suspension and subsequent shaking for 15 min at 80 °C.  The 
maximum labelling yield of 90Y-HSAMMS, achieved under the experimental conditions 
previously described, was 67%, determined by ITLC-SG. A similar result (71%) for the labelling 
yield was obtained by magnetic precipitation. For the following biodistribution studies the main 
step was to remove the excess of unbound 90Y, as free 90Y present in the suspension with labelled 
products may accumulate in the bone. Therefore, the 90Y-HSAMMS were retrieved using 
magnetic decantation, and the supernatant with unbound 90Y was withdrawn and the labelled 
HSAMMS were additionally washed several times with deionizied water, so the radioactivity 
that is present in the bone will be an indicator of the in vivo instability of the 90Y-HSAMMS.  
 
3.7. In vitro stability studies 
The results of both methods (magnetic precipitation and ITLC-SG) showed that less than 
4.1% of the 90Y dissociated from the surface of the 90Y-HSAMMS in saline, and a slightly 
increased percentage (6.9%) in the serum, after 1 h (Fig. 8). Even without the surface 
modification the 90Y remained bound to the HSAMMS for a time period sufficient for a further 
in vivo application. The non-particle bound radioactivity consists only of the free 90Y, moving 
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with the solvent front (Rf =0.9-1.0), and no other degradation products were found. The scanning 
electron microscopy images (not shown) revealed that the microspheres have the same 
characteristic morphology for a 7-day incubation period in HSA at 37 °C. Therefore, the leaching 
of the 90Y is only the result of its detaching from the HSAMMS surface, but not the degradation 
of the HSAMMS.    
 
3.8. Biodistribution study 
The biodistribution and in vivo stability of the labelled HSAMMS were studied, after the 
intravenous injection of approximately 2.5 MBq of 90Y-HSAMMS into the tail veins of rats, up 
to 72 h after the application. 
The 90Y-HSAMMS were completely trapped in the capillary bed of the lungs, which 
served in our experiments as a model for the vascular system of the solid tumors [49]. The high 
uptake (84.81%ID) of the 90Y-HSAMMS 1h after injection (Fig. 9) is expected since the HSA 
microsphere action mechanism is based mainly on the particle size. It was reported that HSA 
microspheres in the size range 5–30 μm were accumulated almost entirely in the lung in the first 
pass of circulation through the pulmonary artery following intravenous administration [50- 52].  
The disappearance of the radioactivity from the lungs was used as a measure of the in 
vivo stability of the microspheres and the attached 90Y. A significantly high percentage of 90Y- 
HSAMMS was present in the lung after 72 h (82.67%ID), showing a satisfactory in vivo stability 
of the 90Y-HSAMMS. Since the labelled HSAMMS retained in the lung for at least one half-life, 
the release of the 90Y is proved by the low radioactivity present in the bone, and consequently the 
damage to the surrounding healthy tissue is negligible. Both the high in vivo retention of 
radioactivity in the lung as well as the in vitro stability studies are proof that the 90Y-HSAMMS 
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stay intact in the lung for at least 72h, giving the possibility to use them in a combined, dual 
radionuclide-hyperthermia therapy. It is reported that the in vivo application of hyperthermia 
showed increased perfusion in the tumor region, leading to a higher oxygen concentration [53]. 
Most human tumors increased the blood flow under hyperthermia and for hours later. Higher 
perfusions can increase the radionuclide delivery and oxygenation required to enhance the free-
radical-dependent cell death in radiotherapy [54]. 
 The results of the biodistribution of the 90Y-HSAMMS 1h after injection (Fig. 9) showed 
that a minor percentage of activity was found in other organs: 4.95 %ID, liver; 4.49% ID, 
intestines; 1.03%ID, kidney and 0.21 %ID, spleen. The tissue distribution of the particulate 
materials depends on the size of the particles injected. Particles larger than 10 μm should be 
located in the lung, particles over 100 nm accumulate preferentially in the liver and spleen (0.2–3 
μm), while smaller particles (<30 nm) tend to accumulate in a relatively higher concentration in 
the bone marrow [55, 56]. The dominant tissue accumulation of 90Y-HSAMMS in one organ, the 
lung, is in agreement with the FESEM analysis of the size distribution of the HSAMMS, showing 
the majority of the particles are larger than 10 μm. The above biodistribution screening method 
in rats was used to evaluate the radiolabelled magnetite particles for possible application in the 
local radionuclide therapy of different tumors. Owing to its size, the 90Y-HSAMMS could be 
used in the SIRT of hepatic metastases by intra-arterial administration.  
Finally, the heating efficiency of the HSAMMS obtained from the power-absorption 
measurements (f=357 kHz, H = 47 kA/m) showed a heating rate of 3.95 K/min, which could be 
enough to reach the temperature range required for thermally induced cell apoptosis by 
hyperthermia. The SPA value obtained from these measurements was 13.8 W/g. Although this is 
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a moderate value when compared to previous reports [6,7], the heating rate could be further 
increased by increasing the actual concentration of the magnetic microsphere in the target area.   
 
4. Conclusions  
We have synthesized a magnetic, microstructured composite based on citric acid-coated 
Fe3O4 nanoparticles encapsulated into biodegradable HSA microspheres. Without any further 
chemical surface modification, in vivo stable 90Y-labelled HSAMMS were prepared. The created 
90Y-HSAMMS should be able to deliver high doses of radiation to the target area. The specific-
absorption-rate measurements showed that radiolabelled HSAMMS are promising microsystems 
for use in a combined cancer treatment based on radionuclide radiation and hyperthermia, 
profiting from the synergy of both protocols. The reported procedure for engineering magnetic 
microspheres can be used for the synthesis of suitable composite materials for cancer therapy as 
well as for drug/radionuclide-delivery magnetic materials.  
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Figure caption 
 
Figure 1. FTIR spectra of citric acid-coated magnetite (Fe3O4/CA) and citric acid (CA)    
Figure 2. X-ray diffraction pattern of HSAMMS. The arrows indicate the indexing of the peaks 
corresponding to the spinel structure of Fe3O4  
Figure 3. TGA curves for citric acid-coated magnetite (Fe3O4/CA) and HSAMMS 
(Fe3O4/CA/HSA) 
Figure 4. Upper panels (a,b): FESEM images of HSAMMS. Lower panels (c,d): 3D 
reconstruction of 50 cross-sectional slices on a single microsphere, showing the distribution of 
the magnetic nanoparticles (blue spots) within the microspheres  
Figure 5. Upper panels: Compositional mapping from EDX analysis of a selected area (pink 
boxes) on a cross-sectioned HSAMMS showing the iron contents (green colour). Lower panel: 
the corresponding EDX spectrum over the same selected area. The small Ga content comes from 
the ion beam  
Figure  6. HRTEM pictures of Fe3O4/CA (a, b) and selected area of HSAMMS (c) 
Figure 7. Magnetization versus field at room temperature. Inset: Hysteresis loop for the 
HSAMMS  
Figure 8. In vitro stability of 90Y-HSAMMS in saline and human serum up to 96 h 
Figure 9. Biodistribution of  90Y-HSAMMS in different tissues after 1, 24, 72 h of intravenous 
administration in normal Wistar rats. The results are expressed as % ID/organ (mean five rats ± 
standard deviations). The inset: results for tissues without lungs 
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